Dr. Peters is the chief executive officer of Yumanity Therapeutics and a member of the board of directors.
Previously, Dr. Peters was president, chief executive officer, and a member of the board of directors of Merrimack Pharmaceuticals. During his tenure, Dr. Peters completed the sale of two approved therapies for more than $1 billion, strengthened the management team, refocused and reprioritized the company’s pipeline on biomarker-defined cancers, accelerated clinical and preclinical development timelines, secured new institutional investors, and improved the company’s financial position. Prior to joining Merrimack Pharmaceuticals, Dr. Peters held positions of increasing responsibility at Sanofi Genzyme, most recently serving as senior vice president, head of global rare disease. Earlier in his career, Dr. Peters held positions of increasing responsibility in the medical organizations at Onyx Pharmaceuticals and Amgen and was the chief executive officer of Mednav. Dr. Peters currently serves as a scientific and corporate advisor and an investor at Aura Biosciences. He is also a co-founder of PIC Therapeutics where he serves as investor and director.
Dr. Peters is a Harvard-trained physician and scientist, has served on the faculty at the Massachusetts General Hospital, and completed a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. He has published more than 100 papers in leading journals and is also an active founder and angel biotech investor in several start-up biopharmaceutical companies.
Dr. Coles is executive chairman and chief executive officer of Cerevel Therapeutics, a Bain-portfolio biotechnology company specializing in the development of new therapies for diseases of the central nervous system. Prior to Cerevel, Dr. Coles served as co-founder and CEO of Yumanity Therapeutics where he was instrumental in establishing and advancing potential new treatments for the treatment of Parkinson’s disease and Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease). Dr. Coles continues to serve as executive chair of the board of directors of Yumanity Therapeutics.
Previously, Dr. Coles served as chair and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen Inc. in 2013. Prior to Onyx, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held several executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co., Inc.
Dr. Coles currently serves on the board of directors of McKesson Corporation and Regeneron and is a member of the board of trustees for Johns Hopkins University. He is also a member of the Council for the Smithsonian’s National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, non-partisan membership organization, think tank and publisher; and a member of the Harvard Medical School Board of Fellows.
Dr. Coles was educated at Johns Hopkins University, earned a medical degree from Duke University, and a master’s degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
Mr. Mohsen is chief business officer of Yumanity Therapeutics. Prior to Yumanity, Mr. Mohsen served as country manager in Canada at Cubist Pharmaceuticals (acquired by Merck), where he led the company’s first international operation from conceptualization through commercialization. In this role, he oversaw the launch of DIFICID (fidaxomicin) and approval of SIVEXTRO (tedizolid) in Canada and led the company’s commercial, scientific and administrative functions. Prior to that, Mr. Mohsen was vice president, strategy and business operations for Optimer Pharmaceuticals, which was acquired by Cubist, and helped establish the commercial infrastructure and led U.S. launch preparedness for DIFICID. Prior to Cubist, Mr. Mohsen held strategic and operational roles of increasing responsibility at Pfizer from 1997 to 2011, including vice president of strategy and vice president, multi-channel management.
Mr. Mohsen holds a B.S. in chemical engineering from Brown University, an M.S. in chemical engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.
Dr. Rhodes is chief scientific officer of Yumanity Therapeutics. Prior to Yumanity, Dr. Rhodes served as vice president, neurology discovery at Biogen, where he led a scientific organization focused on discovery and early development of novel protein and small molecule drugs for the treatment of neurodegenerative diseases. During his tenure at Biogen Idec, Dr. Rhodes’ team delivered nine new chemical entities into preclinical development in areas such as multiple sclerosis (MS), Parkinson’s disease and Alzheimer’s disease. In the Alzheimer’s disease area, Dr. Rhodes and his team played a major role in the preclinical development of BIIB037 (aducanumab), a fully human monoclonal antibody will enter Phase 3 trials later this year. In addition to drug discovery activities, Dr. Rhodes and his team led preclinical research studies in the area of translational biomarkers, played an active role in business development to grow the Biogen discovery pipeline and published seminal research findings characterizing the mechanisms of action of Tecfidera, Biogen Idec’s blockbuster oral therapy for the treatment of relapsing forms of MS.
Prior to joining Biogen Idec, Dr. Rhodes spent a combined 15 years as a discovery research leader at Johnson & Johnson Pharmaceutical Research and Development, LLC (now Janssen), and at Wyeth, where he pursued innovative approaches to the identification of novel ion channel modulators for the treatment of central nervous system diseases.
Dr. Rhodes earned his Ph.D. in anatomy and neurobiology at Boston University and completed postdoctoral training in systems neuroscience at the National Eye Institute, National Institutes of Health.
Bertrand Le Bourdonnec, Ph.D. joined Yumanity Therapeutics in July 2015 as vice president, medicinal chemistry & program management. Prior to Yumanity, Dr. Le Bourdonnec served as vice president discovery chemistry & pharmaceutical research at Cubist Pharmaceuticals, where he led a team of chemists dedicated to the discovery of novel antibacterial and human disease therapeutics. Dr. Le Bourdonnec’s industry experience spans across all stages of research and clinical development, and multiple therapeutic areas including CNS, pain, GI disorders, and infectious disease.
Dr. Le Bourdonnec joined the biopharmaceutical industry in 2000 at Adolor Corporation and held positions of increasing responsibility in the discovery group. After eight years working as a medicinal chemist and discovery program leader, advancing several new molecules into the clinic, he transitioned into development where he led multiple Adolor clinical programs. Following Adolor’s acquisition by Cubist Pharmaceuticals, Dr. Le Bourdonnec joined Cubist’s development group as program leader & senior director, and ultimately moved into his most recent role as vice president discovery chemistry & pharmaceutical research.
Dr. Le Bourdonnec received his chemical engineering degree from the Ecole Nationale Supèrieure de Chimie de Lille (France), his Ph.D. in organic chemistry and a masters degree in drug design from the Institut de Chimie Pharmaceutique de Lille (France). Dr. Le Bourdonnec moved to the United States in 1997, to conduct a post-doctoral fellowship at the University of Minnesota, where he worked, under the supervision of Professor Philip S. Portoghese, distinguished Professor of Medicinal Chemistry, in the design and synthesis of affinity labels for the opioid receptors.
Dr. Le Bourdonnec is co-author of 32 peer-reviewed articles and is listed as an inventor in over 70 worldwide patent applications and 23 issued U.S. patents.
Dr. Robert Scannevin joined Yumanity Therapeutics in April of 2016 as vice president, discovery biology. Dr. Scannevin’s career spans more than 17 years in drug discovery research focused on the development of novel therapeutics and approaches for the treatment of neurodegenerative diseases. Prior to Yumanity, he worked at Biogen, where he served in various positions of increasing responsibility culminating as a senior director in Neurology Discovery. Prior to Biogen, Dr. Scannevin led research initiatives at Wyeth (now Pfizer) and Johnson & Johnson Pharmaceutical Research and Development (now Janssen).
In his time at Biogen, Dr. Scannevin’s laboratory focused on developing disease modifying therapies for the treatment of multiple sclerosis, amyotrophic lateral sclerosis (ALS), Parkinson’s and Alzheimer’s diseases. Dr. Scannevin led discovery programs in Alzheimer’s disease and played a significant role in the preclinical development of BIIB037 (aducanumab), which is currently in phase III clinical trials. In addition, Dr. Scannevin made key contributions to several other discovery programs that have transitioned into clinical development and was heavily involved in the development of dimethyl fumarate (Tecfidera), in which he led preclinical research activity focused on elucidating the mechanism of action of this first-in-class oral therapy. Dr. Scannevin is a recognized leader in the field of fumarate biology.
Prior to starting a research career in industry, Dr. Scannevin earned his Ph.D. at SUNY Stony Brook in the laboratory of Dr. James S. Trimmer, and received postdoctoral training at the Johns Hopkins University School of Medicine in the laboratory of Dr. Richard Huganir. He is a co-author on more than 40 peer-reviewed research articles and an inventor on several patent applications and issued patents.
Ms. Epstein is vice president, finance of Yumanity Therapeutics. Prior to Yumanity, Ms. Epstein served as chief accounting officer of Turbonomic, one of the fastest-growing companies in the virtualization and cloud management industry. In that role, she was responsible for the global finance and accounting functions, including controllership, tax, treasury, financial systems and controls. Prior to joining Turbonomic, Ms. Epstein was chief financial officer of Plastiq, an online payment solution provider. Prior to Plastiq, Ms. Epstein held senior financial roles of increasing responsibility at several fast-growing technology companies in the greater Boston area.
Ms. Epstein holds a B.A. in Psychology from Harvard College and an M.S./MBA in Accounting from Northeastern University’s D’Amore-McKim School of Business. She has held an active CPA license in Massachusetts for over twenty years. In 1993, she won the Gold Medal in Massachusetts on the CPA exam.